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Abstract
Introduction: Integrating standardized measures of HIV stigma and discrimination into research studies of emerging HIV pre-
vention approaches could enhance uptake and retention of these approaches, and care and treatment for people living with
HIV (PLHIV), by informing stigma mitigation strategies. We sought to develop a succinct set of measures to capture key
domains of stigma for use in research on HIV prevention technologies.
Methods: From 2013 to 2015, we collected baseline data on HIV stigma from three populations (PLHIV (N = 4053), commu-
nity members (N = 5782) and health workers (N = 1560)) in 21 study communities in South Africa and Zambia participating
in the HPTN 071 (PopART) cluster-randomized trial. Forty questions were adapted from a harmonized set of measures devel-
oped in a consultative, global process. Informed by theory and factor analysis, we developed seven scales, with values ranging
from 0 to 3, based on a 4-point agreement Likert, and calculated means to assess different aspects of stigma. Higher means
reflected more stigma. We developed two measures capturing percentages of PLHIV who reported experiencing any stigma in
communities or healthcare settings in the past 12 months. We validated our measures by examining reliability using Cron-
bach’s alpha and comparing the distribution of responses across characteristics previously associated with HIV stigma.
Results: Thirty-five questions ultimately contributed to seven scales and two experience measures. All scales demonstrated
acceptable to very good internal consistency. Among PLHIV, a scale captured internalized stigma, and experience measures
demonstrated that 22.0% of PLHIV experienced stigma in the community and 7.1% in healthcare settings. Three scales for
community members assessed fear and judgement, perceived stigma in the community and perceived stigma in healthcare set-
tings. Similarly, health worker scales assessed fear and judgement, perceived stigma in the community and perceived co-worker
stigma in healthcare settings. A higher proportion of community members and health workers reported perceived stigma than
the proportion of PLHIV who reported experiences of stigma.
Conclusions: We developed novel, valid measures that allowed for triangulation of HIV stigma across three populations in a
large-scale study. Such comparisons will illuminate how stigma influences and is influenced by programmatic changes to HIV
service delivery over time.
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1 | INTRODUCTION
A number of efficacious technologies are now available to pre-
vent HIV transmission [1–3], however, their population impact
will depend upon the public’s capacity to take up and adhere
to these technologies [4,5]. HIV stigma and discrimination are
common barriers to HIV prevention, care and treatment ser-
vices, including HIV testing, condom use, adherence to
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antiretroviral therapy (ART), and uptake of prevention-of-
mother-to-child transmission services [6,7]. Fear of experienc-
ing stigma has also been shown to hinder product use among
young women participating in microbicide and pre-exposure
prophylaxis trials in sub-Saharan Africa, potentially contribut-
ing to the failure of these technologies to protect participants
from acquiring HIV [8–10].
Measuring HIV stigma and discrimination in the context of
an HIV prevention intervention requires assessment of stigma
among at least three populations: people living with HIV
(PLHIV), community members (CMs) in the areas where the
biomedical intervention is being implemented, and health
workers (HWs) delivering the intervention. Researchers have
suggested that using “parallel measures” to assess stigma
across these populations will enable the most complete
assessment of stigma by allowing for triangulation of data
across population groups [11,12]. For example, a South African
study developed scales comparing “blame and judgement” and
“interpersonal distancing” among CMs with “self-stigma” and
“expected stigma” among PLHIV [13]. Despite the value of this
approach, no studies have utilized parallel measures to exam-
ine the influence of HIV stigma on biomedical outcomes, such
as HIV incidence and treatment adherence, in a trial setting.
Having validated, parallel measures to assess stigma across
PLHIV, CMs and HWs is a critical first step to facilitating such
research.
More common are scales assessing different domains of
stigma separately among specific populations, including CMs
[14–20], PLHIV [21–27] and HWs [28–36]. While such mea-
sures may provide an in-depth assessment of stigma in a
particular population or setting, they may be less able to
elucidate how stigma operates in the context of a popula-
tion-level biomedical trial with both community and health
setting components. Key domains of stigma that can be
shifted through a trial linked intervention are not always
clearly defined. Additionally, the domains are not measured
consistently across trials and other studies, limiting
comparisons and meta-analyses. Consequently, measures of
stigma are not developed to encourage triangulation of per-
ceptions, attitudes and experiences across different popula-
tions [37].
In this study, we sought to address these limitations by
developing parallel survey questions from a brief set of items
that emerged following a five-year global process to articulate
a practical theoretical framework of the stigmatization process
in the context of HIV and derive standardized indicators of
HIV stigma and discrimination [11,38]. We then explored the
measures in the context of the HIV Prevention Trials Network
(HPTN) 071 (PopART) trial, which tested the impact of a com-
bination HIV prevention package, including universal door-to-
door HIV testing and an offer of ART regardless of CD4
count, on HIV incidence in 21 urban communities in Zambia
and South Africa (seven matched triplets, three in South
Africa and four in Zambia) [39]. Our goals were to develop a
succinct set of valid and reliable measures to capture key
domains of stigma for use in research on HIV prevention tech-
nologies, and to describe and compare the distribution of the
resulting stigma measures across PLHIV, CMs and HWs,
leveraging our unique opportunity to capture data across
these three populations.
2 | METHODS
2.1 | Stigma domains assessed
The key domains of the stigmatization process measured were
derived from “Reducing HIV stigma and discrimination: a
framework for programme implementation and measurement”
[40], which has more recently been broadened to encompass
health-related stigma and discrimination, including HIV [41].
We set out to measure the drivers (i.e. attitudes, such as
shame of association with and judgement towards PLHIV
among CMs and HWs) and manifestations (i.e. internalized
stigma – the application of stigma to oneself [42,43] – and ex-
perienced stigma [7,44] among PLHIV and perceived stigma – a
person’s understanding of how others may act towards, think,
or feel about someone living with HIV [26,43]] – among CMs
and HWs) of HIV stigma [41].
2.2 | Study populations, design and data collection
We collected data in Zambia and South Africa among partici-
pants in the HPTN 071 (PopART) trial and HWs implement-
ing the intervention to simultaneously assess HIV stigma
among three distinct populations: PLHIV, CMs and HWs (Fig-
ure S1). Baseline survey data were collected from PLHIV and
CMs enrolled in the population cohort (PC) of the HPTN
071 (PopART) trial between November 2013 and March
2015. The PC consisted of approximately 2000 men and
women between the ages of 18 and 44 randomly selected
from each of the 21 communities to complete an inter-
viewer-administered questionnaire [39] in their local language.
Participants were asked to self-report their HIV status, and
those who reported a positive HIV status completed an addi-
tional module on HIV stigma. HIV status was later confirmed
by testing blood samples drawn from consenting survey par-
ticipants as previously described [45]. In this analysis, we
included data on self-reported internalized and experienced
stigma among participants in the PC who self-reported living
with HIV and had a confirmed HIV positive test result. We
also included data from a random sample of 20% of PC par-
ticipants from each community who received a series of
questions on HIV stigma-related attitudes and perceptions.
Participants living with HIV were excluded from this commu-
nity member sample.
We also collected baseline data from HWs in study commu-
nities between July 2014 and June 2015. HWs included
health facility staff (e.g. doctors, nurses, pharmacists, counsel-
lors, security guards) working in study communities, Commu-
nity HIV-care Providers (CHiPs) employed by PopART to
deliver the combination prevention package in the community,
and other community-based health workers (CHWs), not
employed by PopART, involved in HIV services in both coun-
tries [46]. HWs who self-reported that they were living with
HIV were not included in this analysis. Due to the low fre-
quency of missing values across the three datasets (2 to
13%), our large sample size, and the nature of the questions,
for which we deemed imputation inappropriate, individuals
missing one or more items in each scale were dropped from
analyses. Analyses confirmed that respondents with missing
data on the stigma questions were not significantly different
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from respondents with complete data on the stigma questions
based on socio-demographic characteristics (data not shown).
2.3 | Scale and experience measure development
Item selection and development of scales and experience mea-
sures were informed by analysis in four phases. In the first
phase, desk review and expert consultation were used to iden-
tify HIV stigma items for inclusion in the PLHIV, community
member, and health worker questionnaires and establish pre-
liminary face validity [47]. Some items were derived from pre-
viously published and validated measures [33,48,49], while
others were developed based on consultation with experts
from the HIV stigma field (Figure 1a-c). We used 11 items
assessing HIV stigma among PLHIV, three of which captured
internalized stigma and used a 4-point agreement rating scale
from 0= “strongly disagree” to 3= “strongly agree” (Figure 1a).
The other eight items captured the frequency of occurrence
(never, not disclosed, once, a few times, often) of reported
experienced stigma in the community (five items) or the
healthcare setting (three items) (Figure 1a). For the HIV fear
and judgement scale among CMs and HWs, items reflected
commonly reported drivers like fear of HIV infection (I fear
that I could contract HIV if I come into contact with the saliva
of a person living with HIV), shame (I would be ashamed if
someone in my family had HIV) and judgement (HIV is punish-
ment from God).
The most common or severe forms of stigma and discrimi-
nation reported by PLHIV in the literature and through expert
consultation informed the items selected to assess stigma per-
ceived by CMs and HWs. For example, CMs and HWs were
asked whether “people thought to be living with HIV were
verbally insulted, harassed, and/or threatened” and whether
“people thought to be living with HIV lose respect and stand-
ing.” Where possible, items were adapted for parallel use
across the three populations. For example, while CMs
responded to the item “people sometimes talk badly about
people living with HIV,” HWs responded to the item “my co-
workers sometimes talk badly about people living with HIV”
and PLHIV responded to the item “people have talked badly
about me because of my HIV status.”
The questionnaires originally included 12 items for CMs not
living with HIV (Figure 1b) and 17 items for HWs (Figure 1c),
which we considered including in the measures. In developing
the scales, we chose to drop two of the items asked of CMs
and three of the items asked of HWs, informed by the litera-
ture and expert consultation. Three of the five items captured
distinct aspects of anticipated stigma related to HIV testing,
ART use, (Figure 1b) and disclosure of HIV status at work
(Figure 1c) that we decided should not be combined with
items assessing stigma related to living with HIV. The two
additional health worker items dropped assessed perceptions
of PLHIV as being “irresponsible.” As these items were not
asked of CMs, we decided to drop them in order to retain the
parallel nature of the measures across the two populations.
In the second phase, we conducted factor analysis to assess
the underlying domains of stigma and reduce the number of
items needed to assess them [50]. While we anticipated the
domains that would be represented based on our previous
research and measurement work [40], we used exploratory
factor analysis as some of the survey items were new or not
previously validated. Initially, all items asked of a specific study
population were included. Eigenvalues were generated and
scree plots visually inspected to suggest the number of factors
that explained most of the variability in the data for each set
of items [51]. To examine the loading strength of items on
each factor, we used iterated principal factor estimation [50]
with oblique (promax) rotation, which allows for correlation
between factors, as we expected the underlying domains of
stigma to be correlated. The item groupings that emerged
were generally consistent with the expected domains of
stigma for all three populations. In the few instances where
the loadings were not as expected, the factor analysis was re-
run following discussion with the research team and based on
relevant theory and factor loadings (i.e. loadings <0.3 were
considered low and those items were dropped).
For example, factor analysis with the community member
data suggested that items assessing perceived stigma in com-
munity and healthcare settings were highly correlated and
could be combined into one measure. However as in other
studies, we wished to explore these domains of stigma sepa-
rately. For example, recent research in The Gambia found that
stigma experienced by PLHIV in healthcare settings led to
more negative outcomes (e.g. delay in accessing treatment,
poor adherence, etc.) than stigma experienced in the commu-
nity, which had little or no impact on health outcomes [49].
Similarly, studies in the US have found associations between
anticipated stigma in the healthcare setting and poor adher-
ence [52], mediated by internalized stigma and depressive
symptoms [53]. Therefore, we chose to keep these two
aspects of perceived stigma separate (Table 1). The same pro-
cess was undertaken with samples stratified by country, sex
and type of HW (for HW items only) to determine if any dif-
ferences in the results existed across these characteristics
among the three study populations (Tables S1-S3). In addition,
factor analysis was undertaken, and factor loadings were
obtained separately for each stigma domain using study sam-
ples where participants responded to all stigma items within a
specific domain (Figure 1a-c).
In the third phase, we calculated Cronbach’s alpha for items
grouped together under our domains of interest to assess the
level of inter-item agreement (i.e. reliability). This was done
using complete data for each stigma domain (Figure 1a-c) and
complete data for CMs not living with HIV (Table 1). We con-
sidered an alpha value of 0.60 to 0.69 as “acceptable,” an
alpha of 0.70 to 0.79 as “good” and an alpha of 0.80 or higher
as “very good,” as suggested by Nunnally [54]. Simple scales
were calculated for each domain of stigma by summing the
scores across the set of items in each domain and dividing by
the total number of items. This method allowed each item to
contribute the same amount to the overall score. Scores ran-
ged between 0 and 3 with higher scores indicating greater
levels of stigma. For the measures of reported experienced
stigma, individual items were dichotomized (never = 0 vs.
ever = 1) then collapsed to create two binary variables
reflecting having experienced stigma in the community in the
previous 12 months and having experienced stigma in the
healthcare setting in the previous 12 months.
Last, we assessed construct validity by examining bivariate
associations between the scales and variables previously
reported as associated with the stigma domains these scales
are intended to represent in the literature [47], including sex,
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Figure 1. a, Responses to, and sources of HIV stigma items asked of people living with HIV. Agree or strongly agree for internalised stigma
and experienced stigma at least once in the community or healthcare settings highlighted in bold. (1) Often: 94 (2.4%); (2) Often: 35 (0.9%);
(3) Once: 70 (1.8%), A few times: 86 (2.2%), Often: 22 (0.6%); (4) Once: 81 (2.0%), A few times: 49 (1.2%), Often: 17 (0.4%); (5) Often: 43
(1.1%); (6) Once: 56 (1.4%), A few times: 51 (1.3%), Often: 13 (0.3%); (7) Once: 102 (2.6%), A few times: 67 (1.7%), Often: 13 (0.3%); (8)
Once: 91 (2.3%), A few times: 64 (1.6%), Often: 9 (0.2%). aAdapted from new item included in the 2015 to 2020 DHS Standard Survey
instrument (https://dhsprogram.com/pubs/pdf/DHSQ7/DHS7-Womans-QRE-EN-07Jun2017-DHSQ7.pdf); bPLHIV Stigma Index survey
(http://www.stigmaindex.org/about-index); cUSAID stigma measures (https://www.icrw.org/wp-content/uploads/2016/10/Working-Report-
Measuring-HIV-Stigma-Results-of-a-Field-Test-in-Tanzania.pdf). b, Responses to, and sources of, HIV stigma items asked of community
members. Agree or strongly agree highlighted in bold. aUSAID stigma measures (https://www.icrw.org/wp-content/uploads/2016/10/Work
ing-Report-Measuring-HIV-Stigma-Results-of-a-Field-Test-in-Tanzania.pdf); b2015 to 2020 DHS Standard Survey Instrument (https://dhspro
gram.com/pubs/pdf/DHSQ7/DHS7-Womans-QRE-EN-07Jun2017-DHSQ7.pdf); cAdapted from new item included in the 2015 to 2020 DHS
Standard Survey instrument; dNew item. c, Responses to, and sources of, HIV stigma items asked of health workers. Agree or strongly agree
highlighted in bold. (1) Agree: 41 (3.0%), Strongly Agree: 31 (2.3%); (2) Strongly Agree: 37 (2.6%); (3) Strongly Agree: 40 (2.8%). aUSAID
stigma measures (https://www.icrw.org/wp-content/uploads/2016/10/Working-Report-Measuring-HIV-Stigma-Results-of-a-Field-Test-in-Ta
nzania.pdf); b2015 to 2020 DHS Standard Survey Instrument (https://dhsprogram.com/pubs/pdf/DHSQ7/DHS7-Womans-QRE-EN-
07Jun2017-DHSQ7.pdf); cNyblade et al. A brief, standardized tool for measuring HIV-related stigma among health facility staff: results of
field testing in China, Dominica, Egypt, Kenya, Puerto Rico and St. Christopher and Nevis. 2013, J Int AIDS Soc; dNew item; eAdapted from
new item included in the 2015 to 2020 DHS Standard Survey instrument (https://dhsprogram.com/pubs/pdf/DHSQ7/DHS7-Womans-QRE-
EN-07Jun2017-DHSQ7.pdf)
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age, education and ever having been tested for HIV (for CMs
and HWs only) [14,55]. Women, younger participants and less-
educated participants were expected to report more internal-
ized stigma [23,56–59]. Among CMs and HWs, participants
who were older, more educated and had tested for HIV were
expected to report less negative attitudes towards PLHIV and
less perceived stigma [14,60,61]. Men were expected to per-
ceive more stigma in the community and healthcare settings,
given the difficulty engaging men in HIV care in sub-Saharan
Africa [62,63]. We used linear regression and performed Wald
tests to assess associations with sex, age, education and ever
tested for HIV on stigma domains adjusting for triplet to take
into account the study design [39]. All statistical analyses were
conducted using the Stata software package (version 14.0,
StataCorp LP, College Station, Texas).
2.4 | Ethical considerations
Prior ethical approval for all study procedures was obtained
from the institutional review boards of the London School of
Hygiene and Tropical Medicine (LSHTM), Stellenbosch Univer-
sity, and the University of Zambia. All participants provided
written informed consent prior to enrolment.
3 | RESULTS
3.1 | Participants
Participants’ characteristics are shown in Table 2. Among
PLHIV, more participants were women (N = 3576/88%), aged
25 to 34 (N = 1874/46%) and unmarried (N = 2097/52%).
Most PLHIV had completed secondary education (N = 2478/
61%). Among community participants, more were women
(N = 3826/66%) than men and between the ages of 18 and
24 (N = 2650/46%) than any other age category. Most com-
munity participants were unmarried (N = 3485/60%), had
completed secondary education (N = 4087/71%), and
reported ever having tested for HIV (N = 4851/84%). More
HWs were Zambian (N = 999/64%), women (N = 1135/73%)
and between the ages of 25 and 34 (N = 591/38%). Slightly
more than half were married (N = 813/52%) and had com-
pleted further than secondary education (N = 822/53%).
Almost all HWs (N = 1508/97%) reported ever having tested
for HIV.
3.2 | Factor analysis and reliability testing
Among PLHIV, three internalized stigma items were assessed
using factor analysis. The items grouped together on one fac-
tor. The scale had high reliability in both the main (a = 0.816;
Figure 1a) and sub-group analyses by country and sex
(Table S3).
Among CMs, 10 items were assessed. In initial analyses, the
items grouped on one factor, an “overall stigma” scale
(a = 0.879, Table 1) that would not allow us to examine the
“fear and shame” and “perceived stigma” domains separately,
as recommended by current stigma theory and intervention
research [37], and would make comparisons of these domains
across the three populations challenging. Therefore we exam-
ined the data using two factors, and found that items grouped
onto a factor capturing fear and judgement (three items:
a = 0.742, Table 1) and a factor capturing perceived stigma in
community and healthcare settings (seven items, a = 0.873,
Table 1).
710 
52.1%
680 
49.9%
520 
38.2%
492 
36.1%
351 
25.8%
287 
20.4%
77 
5.5%
68 
4.8%
235 
16.7%
222 
15.8%
380 
26.3%
303 
21.0%
545 
37.7%
650 
45.0%
339 
23.0%
370 
24.5%
299 
19.8%
Domain: Fear and judgement (α = 0.618, n = 1,362)
559 
41.0%
610 
44.8%
662 
48.6%
582 
42.7%
714 
52.4%
Domain: Perceived sgma in the community (α = 0.647, n = 1,405)
711 
50.6%
274 
19.5%
203 
14.4%
703 
50.0%
766 
54.5%
Domain: Perceived co-worker sgma (α = 0.769, n = 1,445)
647 
44.8%
712 
49.3%
707 
48.9%
665 
46.0%
Items dropped from ﬁnal scale
674 
45.8%
706 
46.7%
677 
44.8%
46 
3.4%
85 
6.2%
223 
16.4%
202 
14.8%
346 
24.6%
689 
49.0%
830 
59.1%
380 
27.0%
314 
22.3%
334 
23.1%
323 
22.4%
156 
10.8%
90 
6.2%
265 
18.0%
316 
20.9%
384 
25.4%
47 
3.5%
95 
7.0%
65 
4.8%
95 
7.0%
61 
4.3%
365 
26.0%
304 
21.6%
87 
6.2%
103 
7.3%
84 
5.8%
107 
7.4%
195 
13.2%
119 
7.9%
152 
10.1%
93 , 6.8%
72 , 5.3% (1)
180 , 13.2%
288 , 21.1%
297 , 21.8%
407 , 29.0%
1,054 , 75.0%
1,134 , 80.7%
467 , 33.2%
417 , 29.7%
418 , 28.9%
430 , 29.8%
193 , 13.4% (2)
130 , 9.0% (3)
460 , 31.2%
435 , 28.8%
536 , 35.4%
HIV is punishment from God (atude)ᵃ (Factor loading: 0.485;
Mean (SD): 0.57 (0.71))
I would be ashamed if someone in my family had HIV (shame)ᵃ˒ᵇ
(Factor loading: 0.688; Mean (SD): 0.58 (0.67))
I avoid physical contact with clients living with HIV (fear)ᶜ
(Factor loading: 0.488; Mean (SD): 0.81 (0.82))
Other people deserve access to health services more than PLHIV (atude)ᵈ
(Factor loading: 0.482; Mean (SD): 0.90 (0.84))
I fear that I could contract HIV if I come into contact with the saliva of a person
living with HIV (fear)ᵃ˒ᵇ (Factor loading: 0.374; Mean (SD): 1.02 (0.82))
People thought to be living with HIV are somemes physically assaulted
(perceived sgma)ᵇ (Factor loading: 0.457; Mean (SD): 1.13 (0.78))
People hesitate to start ARV drugs because they are afraid others will learn they are
living with HIV (ancipated sgma)ᵈ (Factor loading: 0.450; Mean (SD): 1.95 (0.82))
People somemes talk badly about people thought to be living with HIV
(perceived sgma)ᵇ (Factor loading: 0.498; Mean (SD): 1.97 (0.75))
People thought to be living with HIV are verbally insulted, harassed or threatened
(perceived sgma)ᵇ (Factor loading: 0.643; Mean (SD): 1.22 (0.80))
People thought to be living with HIV lose respect and standing (perceived
sgma)ᵇ (Factor loading: 0.548; Mean (SD): 1.21 (0.80))
My co-workers somemes gossip about clients’ HIV test results (perceived sgma)ᵈ
(Factor loading: 0.672; Mean (SD): 1.08 (0.85))
My co-workers somemes talk badly about people thought to be living with
HIV (perceived sgma)ᵉ (Factor loading: 0.595; Mean (SD): 1.17 (0.84))
My co-workers somemes treat PLHIV poorly when providing them with health
services (perceived sgma)ᵈ (Factor loading: 0.761; Mean (SD): 0.79 (0.74))
My co-workers somemes verbally insult clients living with HIV (perceived sgma)ᵉ
(Factor loading: 0.685; Mean (SD): 0.66 (0.71))
Health workers living with HIV do not disclose their status at work for fear
of losing their job (ancipated sgma)ᵈ (n=1,473) (Mean (SD): 1.21 (0.95))
People get HIV because they engage in irresponsible behaviors
(atude)ᵃ (n=1,511) (Mean (SD): 1.12 (0.87))
If someone asks for an HIV test, they have probably behaved
irresponsibly (atude)ᵈ (n=1,512) (Mean (SD): 1.26 (0.89))
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Strongly Disagree Disagree Agree Strongly Agree
(c)
Figure 1. Continued
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However, based on previous research in the Gambia men-
tioned above, we determined that it was important to capture
perceptions of stigma in community and healthcare settings
distinctly [49]. We also wanted to be able to compare CMs’
perceptions with actual experiences of PLHIV in these two
contexts. Thus we created two perceived stigma scales. One
to assess stigma perceived in the community and the other to
assess stigma perceived in the healthcare setting. Item agree-
ment for the three community member scales was generally
quite high: fear and judgement (three items, a = 0.742,
Table 1), perceptions of stigma in the community (five items,
a = 0.843, Table 1) and perceptions of stigma in the health-
care setting (two items, a = 0.763, Table 1). Sub-group factor
analysis by country and sex also supported high reliability in
these domains (Table S1).
Among HWs, 14 items were assessed. In factor analysis,
these items grouped into three separate factors with accept-
able reliability representing fear and judgement (five items,
a = 0.618; Figure 1c), perceived stigma in the community (five
items, a = 0.647; Figure 1c) and perceived co-worker stigma
Table 2. Sociodemographic characteristics and stigma measures among people living with HIV, community members and health
workers in South Africa and Zambia
Sociodemographic characteristics
People living with HIV
N = 4053
N (%)
Community members
N = 5782
N (%)
Health workers
N = 1560
N (%)
Country
Zambia 2285 (56.4) 3068 (53.1) 999 (64.0)
South Africa 1768 (43.6) 2714 (46.9) 561 (36.0)
Type of HW
HFS – – 829 (53.1)
CHiP – – 508 (32.6)
CHW – – 223 (14.3)
Gender
Male 477 (11.8) 1956 (33.8) 425 (27.2)
Female 3576 (88.2) 3826 (66.2) 1135 (72.8)
Age
18 to 24 450 (11.1) 2650 (45.8) 163 (10.4)
25 to 34 1874 (46.2) 2082 (36.0) 591 (37.9)
35 to 44 1729 (42.7) 1050 (18.2) 370 (23.7)
45+ – – 436 (27.9)
Marital status
Not married 2097 (51.7) 3485 (60.3) 747 (47.9)
Married 1956 (48.3) 2297 (39.7) 813 (52.1)
Education
Less than secondary 1416 (34.9) 1321 (22.8) 75 (4.8)
Completed secondary 2478 (61.1) 4087 (70.7) 663 (42.5)
Further 159 (3.9) 374 (6.5) 822 (52.7)
Ever tested for HIV
No – 931 (16.1) 52 (3.3)
Yes – 4851 (83.9) 1508 (96.7)
Stigma scales and measures
(% agreement with any statements) n/N (%) n/N (%) n/N (%)
Fear and judgement – 1227/5415 (22.7) 618/1362 (45.4)
Internalized stigma 887/3933 (22.6) – –
Perceived stigma in community – 3338/5256 (63.5) 1306/1405 (93.0)
Experienced stigma in the community 868/3954 (22.0) – –
Perceived stigma in the healthcare setting
(CMs)/perceived co-worker stigma (HWs)
– 1607/5306 (30.3) 627/1445 (43.4)
Experienced stigma in healthcare settings 284/3974 (7.1) – –
CHiP, community HIV care providers; CHW, community-based health worker delivering HIV-related services; HFS, health facility-based staff.
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(four items, a = 0.769; Figure 1c). Sub-group factor analysis
confirmed acceptable reliability for all three scales by country,
sex and type of health worker. However, Cronbach’s alpha was
below 0.6 for the fear and judgement domain and the per-
ceived stigma in the community domain among CHWs and
CHiPs (Table S2).
3.3 | Scales and experience measures
We ultimately created seven scales. Mean scores for each
scale are shown in Tables 3a-c. Means equal to or less than
1.0 indicate that on average, participants disagreed with the
attitudinal statements. For PLHIV, the internalized stigma
scale had a mean of 0.84 (standard deviation (SD) = 0.63)
(Table 3a), with 22.6% reporting any internalized stigma in the
past 12 months (Table 2). Experienced stigma and discrimina-
tion in the community and healthcare settings in the past
12 months were reported by 22.0% and 7.1% of PLHIV
respectively (Table 2).
For CMs, the mean score was 0.81 (SD = 0.58) for HIV
fear and judgement, with 22.7% agreeing with at least one of
the three statements, 1.24 (SD = 0.66) for perceived stigma
in the community, with 63.5% agreeing with at least one of
the five statements, and 1.02 (SD = 0.74) for perceived
stigma in the healthcare setting, with 30.3% agreeing with at
least one of the two statements (Tables 2 and 3b).
Among HWs, the mean score was 0.78 (SD = 0.49) for fear
and judgement, with 45.4% agreeing with any of the five state-
ments, 1.50 (SD = 0.51) for perceived stigma in the commu-
nity, with 93.0% agreeing with any of the five statements, and
0.92 (SD = 0.60) for perceived co-worker stigma, with 43.4%
agreeing with any of the four statements (Tables 2 and 3c).
3.4 | Stigma and sociodemographic factors
As expected, internalized stigma was associated with age
among PLHIV. Older participants reported slightly less inter-
nalized stigma (aged 35 to 44 years, mean = 0.81; SD = 0.63)
than younger participants (aged 18 to 24 years, mean = 0.89;
SD = 0.64; p = 0.048). PLHIV aged 35 to 44 were more likely
to report experiencing stigma and discrimination in the com-
munity than PLHIV aged 18 to 24 (OR: 1.50; 95% CI: 1.14 to
1.97). PLHIV who completed secondary school were less likely
than PLHIV with less than secondary education to report
experienced stigma in the community (OR: 0.81; 95% CI: 0.68
to 0.96). While mean internalized stigma scores were higher
for PLHIV with less education, the observed difference was
not significant. Unexpectedly, internalized stigma was not
associated with sex. Experienced stigma in the healthcare set-
ting was more likely to be reported by PLHIV aged 25 to 34
(OR: 1.87; 95% CI: 1.11 to 3.14) and those aged 35 to 44
(OR: 2.04; 95% CI: 1.21 to 3.42) compared to younger PLHIV
aged 18 to 24 years. Experienced stigma did not differ by sex
(Table 3a).
Contrary to our hypotheses, HIV fear and judgement did
not vary significantly by sex, age, education or ever tested for
HIV among CMs. Perceptions of stigma in the community
were not associated with sex, but were significantly associated
with education and ever tested for HIV in the opposite direc-
tion as expected. Unexpectedly, those with post-secondary
education (mean = 1.42; SD = 0.66; p < 0.001) and those
who had ever tested for HIV (mean = 1.25; SD = 0.64;
p < 0.001) perceived more stigma in the community than
those with less than secondary education and those who had
not tested for HIV respectively. Perceived stigma in the
healthcare setting was associated with both sex and educa-
tion. As expected, men (mean = 1.07; SD = 0.75; p = 0.006)
perceived more stigma in healthcare settings than women.
Unexpectedly, those with secondary (mean = 1.04; SD = 0.73;
p < 0.001) or post-secondary education (mean = 1.20;
SD = 0.79; p < 0.001) perceived more stigma in the health-
care setting than those with less than secondary education
(Table 3b).
Among HWs, fear and judgement were significantly associ-
ated with age, education and ever having tested for HIV. Con-
trary to our hypotheses, younger (aged 18 to 24, mean = 0.81;
SD = 0.48; p = 0.015) and older (aged 45 + years,
mean = 0.84; SD = 0.53, p = 0.015) HWs had higher scores
than HWs aged 25 to 44 years, reflecting more negative atti-
tudes. As expected, HWs with less than secondary education
(mean = 0.92; SD = 0.66; p < 0.001) and those who had never
tested for HIV (mean = 1.02; SD = 0.58; p = 0.002) reported
more negative attitudes. Perceived stigma in the community
was significantly associated with sex, age and education. As
expected, male HWs (mean = 1.52; SD = 0.50; p = 0.019) and
younger HWs aged 18 to 24 (mean = 1.60; SD = 0.41;
p = 0.027) perceived more stigma in the community. Unexpect-
edly, HWs who had completed secondary education
(mean = 1.59; SD = 0.49; p < 0.001) perceived more stigma in
the community and perceived more co-worker stigma in the
healthcare setting (mean = 0.94; SD = 0.63; p = 0.012). Per-
ceived co-worker stigma was significantly associated with sex
and age, with male HWs (mean = 1.01; SD = 0.62; p = 0.022),
and those over 35 perceiving more co-worker stigma (35 to 44:
mean = 0.98; SD = 0.58; p = 0.019; 45+: mean = 0.98;
SD = 0.63). Ever tested for HIV was not associated with per-
ceived stigma in the community or perceived co-worker stigma
for HWs (Table 3c).
4 | DISCUSSION
We developed seven scales and two experience measures
using 35 items capturing drivers and manifestations of HIV
stigma and discrimination and established their reliability and
validity across three populations in Zambia and South Africa.
The health worker scales are applicable in both countries and
with a broad range of HWs. Our study is the first to create
theory-based, parallel measures of stigma across PLHIV, CMs
and HWs in the same study population. More CMs and HWs
reported perceived stigma in community and healthcare set-
tings than the proportion of PLHIV who reported experiences
of stigma in both settings. Men perceived more stigma
towards PLHIV in healthcare settings, which may be a factor
influencing male engagement in HIV services.
A few limitations in our approach should be mentioned.
First, we did not examine predictive validity, as we only
included baseline data in the present analyses. Future analyses
are planned to assess how well our parallel measures of
stigma predict relevant outcomes such as ART adherence
among PLHIV. Second, while the parallel measures developed
allow for quantitative assessment of stigma, it should be noted
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that stigma and discrimination emerge from a social process
influenced by power and inequality [64]. Qualitative social
science investigations that aim to understand the social
dimensions of stigma, such as those conducted in the HPTN
071 (PopART) trial, will complement the scales measured here
by describing how stigma is influencing and being influenced
by social and inter-personal processes [65]. Third, men were
underrepresented in the population cohort (PC) of the HPTN
071 (PopART) trial [66], despite repeat visits to households,
additional recruitment efforts added, and continuous commu-
nity engagement efforts [67]. The higher level of perceived
stigma in the healthcare setting reported by men in the pre-
sent study suggests that stigma may have discouraged men’s
participation in the trial. Given this, it is possible that the
prevalence of the various stigma domains presented in the
present paper across our three populations may be underesti-
mates, especially for men in the study communities. Lastly,
assessing stigma quantitatively among members of key popula-
tions in the PC was not within the scope of our study. Thus,
we were not able to assess intersectional stigma nor validate
our stigma measures among key populations living with HIV.
Key populations were included in our social science investiga-
tions and analyses of these data are forthcoming. Despite
these limitations, our study draws strength from being the
first to develop and validate parallel measures of stigma
across three populations in the context of a large HIV preven-
tion trial, including the first ever population-based, random
sample of PLHIV.
Our resulting scales measured different domains of stigma
than the parallel scales developed by Visser et al. [13]. For
CMs and HWs, our “fear and judgement” scales combine some
of the items assessing “blame and judgement” and “interper-
sonal distancing” with items assessing shame and fear of HIV
infection through casual contact with PLHIV. Our parallel mea-
sures for CMs and HWs also differed in that they included
two new scales to assess perceptions of stigma occurring in a
community or healthcare setting, which previous research sug-
gests may prevent or delay engagement with health services
[49]. Like Visser, we created a scale to capture internalized, or
“self-stigma,” among PLHIV. Similar to previous research in
Bangladesh and South Africa, we found that older age was
associated with lower levels of internalized stigma [24,68]. In
contrast to Visser’s scale of expected stigma, we developed
two composite measures that capture reported experiences of
stigma and discrimination in community and healthcare set-
tings over the past 12 months. This enabled us to assess the
baseline prevalence and characteristics of two critical domains
of HIV stigma that have been shown to be associated with
HIV-related health seeking behaviour among PLHIV [49,69].
Similar to Visser et al. and Zelaya et al., the parallel scales
among the community and PLHIV samples showed good to
very good internal consistency [13,26]. Among the complete
healthcare worker sample, the internal consistency of the “fear
and judgement” scale and “perceived stigma in the community”
scales was lower than desired, yet acceptable for making
group comparisons (a > 0.60) [54]. The findings from the sub-
group analyses of the stigma scales among the three different
cadres of HWs suggest that some items may be more appro-
priate for facility-based staff. For example, two items on the
“fear and judgement” scale (“Other people deserve access to
health services more than PLHIV” and “I fear that I could
contract HIV if I come into contact with the saliva of a person
living with HIV”) had low factor loadings for CHiPs only. These
items may not resonate with CHiPs, who have chosen to pro-
vide door-to-door HIV testing, counselling and referral ser-
vices for PLHIV in the community and have been trained on
transmission of HIV and provision of culturally sensitive ser-
vices. The items we used in this research were adapted from
a facility-based stigma survey [33]. As the factor analyses of
the other two scales (i.e. perceived stigma in the community
and perceived co-worker stigma) were comparable in the com-
bined health worker sample and the sub-group analyses, we
are comfortable recommending the utility of the three scales
in combined analyses with the health worker population. How-
ever, future stigma research could consider alternative items
that may be more relevant for assessing the drivers of stigma
in the context of community-based HIV-related service provi-
sion.
Similar to a multi-country study conducted among HWs
[33], fear and judgement among CMs and HWs in our study
population were low, reflecting little fear, shame and judge-
ment towards PLHIV. These low levels may explain why we
did not see any differences in negative attitudes across socio-
demographic characteristics and suggests that interventions to
reduce negative attitudes towards PLHIV may not need to be
targeted to specific demographic groups. Conversely, percep-
tions of stigma in the community and healthcare settings were
high for both groups, with HWs perceiving considerably more
stigma occurring in the community setting. We were not able
to compare our findings with other studies due to the paucity
of published data on this aspect of stigma among CMs and
HWs. However, we do know that in our study population, the
proportions of PLHIV reporting internalized and experienced
stigma were significantly associated with the level of per-
ceived stigma in the community reported by CMs, but not
with the level reported by HWs [70]. This finding resonates
with research in the US that found potential causal pathways
among these different dimensions of stigma, in particular that
women living with HIV who perceive high levels of stigma in
the community and in healthcare settings are more likely to
internalize stigma [53]. Our findings that men and more edu-
cated CMs and HWs perceived more stigma suggest that
interventions to reduce perceived stigma may need to be tar-
geted to specific demographic groups. Further research is
warranted to better understand how perceived stigma is oper-
ating in communities and healthcare settings, why HWs might
perceive more stigma than CMs, and how high levels of per-
ceived stigma may impact health outcomes for PLHIV.
Nearly one in four PLHIV reported internalized or experi-
enced stigma in the last year, and the levels of stigma did not
differ by sex, suggesting that interventions to reduce these
key stigma manifestations may be needed for both men and
women. While reports of experienced stigma in the healthcare
setting were relatively low, previous research suggests that
such experiences can be particularly damaging and impactful
for PLHIV, and anticipation of stigma in this setting can have
significant impacts on HIV prevention and treatment utiliza-
tion [71]. Comparison of the parallel measures developed does
suggest some unique domains of stigma for each population
that may require specific intervention. For example, stigma
reduction efforts for young PLHIV should likely focus on
addressing and overcoming internalized stigma, whereas older
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PLHIV may require support to cope with stigma experienced
in the community and healthcare settings.
Likewise, efforts with HWs could emphasize the high levels
of perceived stigma in the community compared to actual
experiences of stigma reported by PLHIV, which may help
HWs living with HIV to feel more comfortable disclosing their
status and accessing care at the facilities and communities in
which they work [72]. Our finding that men perceived more
stigma towards PLHIV in the healthcare setting than women
could partially explain why engaging men in HIV-related health
services has been challenging in sub-Saharan Africa to date
[73], suggesting that interventions to address perceptions
about HIV stigma in communities may be needed to enhance
male engagement in the HIV prevention and treatment cas-
cades. Having access to parallel data on stigma domains that
can be influenced by interventions could be very useful for
policy makers and programme planners as they determine
where to direct limited financial resources for national-level
HIV responses.
5 | CONCLUSIONS
The successful development of parallel scales in this study will
enable future research to answer a number of key questions
for the delivery of HIV services, such as whether internalized
stigma is a greater barrier to ART uptake and engagement in
care among PLHIV than experienced stigma, and to compare
the impact of different types of stigma on the uptake of HIV
prevention and care services longitudinally. Knowing the
answers to these questions could then guide efforts to
address the most pressing domains of stigma and in turn
remove barriers to HIV prevention, care and treatment.
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